Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2002
11/05/2002US6475796 Vascular endothelial growth factor variants
11/05/2002US6475644 Medical devices for delivery of targeted radioisotopes
11/05/2002US6475534 Ginkgo biloba composition, method to prepare the same and uses thereof
11/05/2002US6475493 Controlled release pellet formulation
11/05/2002US6475480 Use of adenoviral E4 reading frames to improve expression of a gene of interest
11/05/2002CA2038379C Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
11/04/2002WO2004001058A2 Transcription factor modulating compounds and methods of use thereof
10/2002
10/31/2002WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002WO2002086123A2 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
10/31/2002WO2002086105A1 Delivery of polynucleotide agents to the central nervous sysstem
10/31/2002WO2002086104A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002WO2002086087A2 Cytokine protein family
10/31/2002WO2002086085A2 Human timp-1 antibodies
10/31/2002WO2002086078A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
10/31/2002WO2002086069A2 Secreted proteins
10/31/2002WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002WO2002085925A2 Melanocortin receptor ligands
10/31/2002WO2002085906A2 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002WO2002085894A1 Arylindenopyridines with pde inhibiting activity
10/31/2002WO2002085891A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
10/31/2002WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002WO2002085887A1 Phenyl- and pyridyl-piperidines with tnf activity
10/31/2002WO2002085868A1 Benzoxazinone derivatives for use in the treatment of angiogenesis
10/31/2002WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002WO2002085850A1 Cyclic amidine derivative
10/31/2002WO2002085844A1 New compounds
10/31/2002WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002WO2002085839A1 Fused bicyclic or tricyclic amino acids
10/31/2002WO2002085459A2 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002WO2002085414A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
10/31/2002WO2002085387A2 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions
10/31/2002WO2002085386A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002WO2002085385A2 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa
10/31/2002WO2002085384A2 Lubricious coatings for substrates
10/31/2002WO2002085379A1 Method for improving vascular access in patients with vascular shunts
10/31/2002WO2002085376A2 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
10/31/2002WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002WO2002085361A1 Benzimidazolone compounds
10/31/2002WO2002085357A1 Nociceptin analogs
10/31/2002WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002WO2002085299A2 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002WO2002085293A2 Production of alpha-lipoic acid
10/31/2002WO2002085124A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002WO2002070565A9 High-affinity antagonists of elr-cxc chemokines
10/31/2002WO2002068390A8 Diamides which inhibit tryptase and factor xa activity
10/31/2002WO2002066681A9 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002060949A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002WO2002041896A3 Use of thienopyrimidines
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002013806A3 Compositions containing hypotriglyceridemically active stilbenoids
10/31/2002WO2001087348A3 Multifunctional nanodevice platform
10/31/2002WO2001055432A3 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications
10/31/2002WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020161262 Use treating various medical conditions, including pain
10/31/2002US20020161191 Novel Imidazoline receptor homologs
10/31/2002US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002US20020161039 Crystalline choline ascorbate
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161030 Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161022 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/31/2002US20020161020 Stablization of quinapril using magnesium oxide
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002US20020161008 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161000 Treating diseases resulting from tissue breakdown such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, atherosclerosis, and osteoporosis
10/31/2002US20020160999 Treatment of diseases or disorders of the central nervous system
10/31/2002US20020160997 Novel indole derivatives
10/31/2002US20020160992 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
10/31/2002US20020160988 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160982 Modafinil compound and cyclodextrin mixtures
10/31/2002US20020160963 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
10/31/2002US20020160955 Protein variants
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160933 Methods and compositions for producing a neurosalutary effect in a subject
10/31/2002US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160044 Liver selective drug therapy
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020160003 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual
10/31/2002CA2843001A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002CA2445168A1 Human timp-1 antibodies
1 ... 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 ... 1595